Actively Recruiting

Phase Not Applicable
Age: 18Years - 35Years
All Genders
Healthy Volunteers
NCT06214065

Modulating Temporoparietal Junction Mentalizing-Related Activity in Autism Spectrum Disorder (ASD) Using Transcranial Magnetic Stimulation (TMS)

Led by Yale University · Updated on 2026-03-27

80

Participants Needed

1

Research Sites

182 weeks

Total Duration

On this page

Sponsors

Y

Yale University

Lead Sponsor

N

National Institute of Mental Health (NIMH)

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this observational study is to test the modulation effect of different transcranial magnetic stimulation (TMS) on the neural network supporting our ability to create mental representations of others (also known as mentalizing) in young adults with autism. The main question it aims to answers is can stimulation of the right temporoparietal junction can change brain activity related to mentalizing during social interaction in the stimulation area and other brain areas connected to it. Researchers will compare results to a group of individuals without autism to see if the patterns of neural activity change are similar between the groups. Participants will undergo assessment of their clinical traits and social skills and baseline MRI scan. They will attend three additional visits that include TMS session and functional MRI scans before and right after TMS.

CONDITIONS

Official Title

Modulating Temporoparietal Junction Mentalizing-Related Activity in Autism Spectrum Disorder (ASD) Using Transcranial Magnetic Stimulation (TMS)

Who Can Participate

Age: 18Years - 35Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Estimated full-scale IQ >80
  • Right handed
  • Fluent in English
  • Individual can cooperate with all study's procedures
  • No history of neurological disorder (e.g., epilepsy) or neurosurgery
  • No major medical condition (e.g., cancer, heart failure)
  • No history of significant head injury
  • No primary relatives with history of neurological disorder with potentially hereditary basis, including epilepsy or MS
  • No current use of psychotropic or anti- or pro-convulsant medications
  • No current substance use (determined by urine screen and breathalyzer in all visits)
  • Negative urine pregnancy test at time of MRI scans for women
  • No contraindications to MRI (e.g., in-body metal implant, severe claustrophobia)
  • No previous participation in this lab's study including the Domino fMRI task
  • For ASD participants: Stable medication treatment 4 weeks before enrollment
  • For control group: No current or history of psychiatric disorders other than simple phobia, and no primary relatives with ASD
Not Eligible

You will not qualify if you...

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Olin Neuropsychiatry Research Center (ONRC)

Hartford, Connecticut, United States, 06106

Actively Recruiting

Loading map...

Research Team

M

Michal Assaf, MD

CONTACT

V

Vaughn R Steele, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

NON_RANDOMIZED

Model

CROSSOVER

Primary Purpose

OTHER

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here